- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- FDA approves one-week antifungal drug made by Valeant
- Target to expand omnichannel offerings in Q3 as new mobile app sees strong growth
- Ken Martindale appointed president, COO of Rite Aid
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
MONTREAL — The Federal Trade Commission has approved a deal by Valeant Pharmaceuticals International to buy a Scottsdale, Ariz.-based drug maker.
Valeant said the FRC had finished reviewing its planned acquisition of Medicis Pharmaceutical and allowed the waiting period required under merger and acquisition laws to terminate early.
Valeant said the deal is still subject to conditions like the approval of Medicis' stockholders, who will have a special meeting on Dec. 7. Medicis makes drugs for asthma, fungal infections and skin conditions like acne and eczema.